Novartis Expects To Reveal the New Lung Drug Soon

.

Novartis Expects To Reveal the New Lung Drug Soon

After three clinical trials, Novartis is positive about the lung drug to hit the market soon. The drug has been designed for patients suffering from chronic obstructive pulmonary disease (COPD), often known as smokers' cough.

The drug, QVA149, is the combination of Novartis' Onbrez and its other lung drug NVA237. Till now, the company has carried three clinical trials, which have showed positive results for the new drug. The three trials were a part of the 10 trials involved in total. The total analysis is expected to complete by 2012.

The first trial proved that the drug alone showed better results than combined results of both Onbrez and NVA237. The second trial of the drug showed that the patients were able to develop patience to suffer. Moreover, the third trial proved that it was equivalent to its competitors in case of tolerability and safety.

The company has high hopes with this drug. It is expecting that the drug will be able to let the company to take on market leader GlaxoSmithKline.

Kepler Capital Markets analyst Martin Voegtli, said “We model $2.9 billion peak sales by 2020 for QVA149, which is expected to form the most important portfolio addition over the next few years. Filing in Europe is expected by year-end 2012”.


Latest News

Lara Casalotti finds stem cell donor
Sending mentally ill people long distances must stop, panel
Zenefits CEO Leaves Over Compliance Issues COO Takes Over
Apollo Education Group will be Acquired by a Group of Private Investors
BOJ’s Negative Interest Rate Expected to have Major Influence on Japan’s Banks
21st Century Fox Lowers Full Year Earnings Guidance
Taco Bell’s Mystery Food comes to Town; “Quesalupa’ Introduced in Super Bowl Sun
Chipotle will Shutter Restaurants on Monday for Four Hours for Food Safety Meeti
China’s Sluggish Growth, Drop in Commodity Prices makes Markets Unsure about Pol
U.S Job Growth and Increase in Average Hourly Wages Brings Optimism
Weaker Economic Data May Continue Dovish Outlook
Texas Supermarket Chain HEB Recalls its Ice cream Flavor due to Possible Presenc